Oxford BioDynamics Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing personalized medicine tests based on 3D genomic biomarkers, has signed a Human Material and Data Transfer Agreement with Oregon Health & Science University (OHSU) as part of its EpiSwitch™ COVID-19 disease severity test program. Some people infected with COVID-19 become severely ill and hospitalized, while many only experience mild illness. Under the terms of the agreement, samples from O